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Both IL-10 and STAT3 are in the same signal transduction pathway, with IL-10-bound IL10 receptor (R) acting through STAT3 for
anti-inﬂammatory eﬀect. To investigate possible therapeutic synergism, we delivered both full-length wild-type human (h) STAT3
andhIL-10genesbyseparateadenoassociatedvirustype8(AAV8)tailveininjectionintoLDLRKOonHCD.Comparedtocontrol
Neo gene-treated animals, individual hSTAT3 and hIL-10 delivery resulted in signiﬁcant reduction in atherogenesis, as determined
by larger aortic lumen size, thinner aortic wall thickness, and lower blood velocity (all statistically signiﬁcant). However, dual
hSTAT3/hIL-10 delivery oﬀered no improvement in therapeutic eﬀect. Plasma cholesterol levels in dual hSTAT3/hIL-10-treated
animals were statistically higher compared to hIL-10 alone. While no advantage was seen in this case, we consider that the dual
gene approach has intrinsic merit, but properly chosen partnered genes must be used.
1.Introduction
Animal and humans studies have lead to at least a
partially understanding of the role of inﬂammatory cells
in atherogenesis [1]. From this understanding we now
know that atherosclerotic plaque is essentially a benign
immune/inﬂammatory cell tumor. A cascade of events is
believed to result in the development of such plaque.
Endothelial cells become activated by shear stress or other
insults. These activated endothelial cells then stimulate traf-
ﬁcking of immune cells into the intimal area, most notably
monocytes. Monocytes are the precursors of macrophages
and, ultimately, of lipid engorged macrophages, known as
foam cells. These foam cells ultimately form the major mass
of early intermediate atherosclerotic plaque. Inﬂammatory
cytokines are overexpressed in this environment, changing
the arterial lumen milieu from an antithrombogenic state
to a prothrombotic one. In this altered milieu activated
endothelium displays decreased nitric oxide synthesis and an
increasedoxidativestate,which,inturn,increasesinﬂamma-
tion [2, 3].
There are now a variety of anti-inﬂammatory genes
already identiﬁed which might be used with therapeutic
eﬀect. Cytokine interleukin 10 (IL-10) has been signiﬁcantly
studied as a strong general inhibitor of immune response
and inﬂammation. In mouse models IL-10 gene delivery
does result in moderate antiatherosclerotic eﬀects, shown by
multiple groups [4–6]. It is also known that IL-10 signaling
goes through, requires, signal transducer and activator
of transcription 3 (STAT3) [7, 8] and that STAT3 gene
delivery also results in inhibition of atherosclerotic plaque
formation [9]. Yet, while individual IL-10 and STAT3 gene
delivery were eﬃcacious, some disease remained. Thus, yet
stronger gene eﬀectors are desirable. This issue is particularly
important considering that the most likely candidates for
antiatherosclerosis gene therapy will have signiﬁcant estab-
lished disease.2 International Journal of Vascular Medicine
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Figure 1: IL-10 signal transduction and hypothesized treatment by dual gene therapy. (a) shows multiple possible IL-10 signal transduction
pathways. The STAT3 pathway results in an anti-inﬂammatory response. (b) shows our attempt to enhance IL-10 signaling at two points
with the hypothesis that enhanced gene expression of the anti-inﬂammatory gene set would occur. The gene delivery is indicated by larger
font and bolded IL-10 and STAT3. More powerful signal transduction is represented by larger arrows and larger font.
In the ﬁeld of cancer it is well known that multiple
protooncogene mutations often take place within a single
signal transduction pathway, resulting in continuous and
permanent signaling within those malignant cells, most
commonly signaling continuous cell division [10]. This
is a powerful form of functional gene cooperation which
ultimately results in many cancer deaths. We considered
this cancer-causing gene signaling cooperation to have a
powerful phenotype and that this strategy could potentially
be useful for addressing atherogenesis. We hypothesized that
perhaps the overexpression of two genes within a common
signal transduction pathway, using anti-inﬂammatory genes
in place of oncogenes, may result in a beneﬁcial gene
cooperationandprovideanevenstrongeranti-inﬂammatory
eﬀect. Moreover, this is a novel gene therapy approach, not
attempted before.
We have previously studied the individual use of the IL-
10 and STAT3 genes to lower inﬂammation and atheroge-
nesis [4, 9]. These two genes are located within the same
anti-inﬂammatory signal transduction network, with IL-10
acting through STAT3 [7, 8]. To test the hypothesis that
two anti-inﬂammatory genes of the same pathway will have
higher eﬃcacy than one, hIL-10 plus hSTAT3 was delivered
using adenoassociated virus (AAV) as a gene delivery vector
[4, 9], and the resulting therapeutic eﬀect was studied in
a LDLR KO mouse-HCD model. AAV is an outstanding
gene therapy/gene delivery vector, having been used since
1984 [11–13], and does not contribute to inﬂammation
[14]. Contrary to our thoughtful planning, no increased
therapeutic beneﬁt was observed when using STAT3/IL-10
together, and, in fact, cholesterol levels were higher in the
dual-gene-treated animals.
2. Methods
2.1. Generation of Recombinant AAV Virus. Construction
and generation of AAV/Neo, AAV/hSTAT3, and AAV/hIL-10
recombinant virus have been described previously [4, 7, 9].
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Figure 2: Structure of AAV vectors and experimental scheme. (a)
showsthebasicstructureofthethreeAAVvectorsusedinthisstudy.
(b) shows the experimental scheme and data collected.
The virus stocks were generated and tittered by dot blot
hybridizationasdescribedpreviously[4,7,9].Thetiterswere
calculated to be about 1 × 109 encapsidated genomes per mL
(eg/mL).International Journal of Vascular Medicine 3
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Figure 3:ExpressionofthedeliveredhSTAT3andIL-10.RelativeexpressionofhSTAT3(a)andIL-10(b)genesbyreal-timequantitativePCR
from aorta of 3 mice in each group. For qRT-PCR the quantity of RNA for each gene was normalized to GAPDH in the same sample. Data
shown are mean ± SE. (c) shows the levels of total cholesterol. Note that cholesterol levels of the hSTAT3-plus-hIL-10-treated animals had
signiﬁcantly higher cholesterol levels than animals treated with individual genes. (d) shows the animal weights at the end of the experiment.
The key at the bottom is used for both panels (c) and (d).
2.2. Animal Treatments. Low-density lipoprotein recep-
tor (LDLR) knockout mice (B6;129S7-Ldlrtm1Her/J) were
obtained from Jackson Laboratories (Bar Harbor, Me, USA).
T w og r o u p so fm a l em i c ew e i g h i n g1 6 – 2 0g r a m sw e r e
i n j e c t e dw i t hA A V - N e oa n dA A V - S T A T 3v i r u se a c ha ta
titer of 1 × 109 eg/mL via tail vein injections of 200µl
virus/mouse, followed by two booster injections at an
interval of less than one week. The animals were started on
highcholesteroldiet(HCD)of4%cholesteroland10%Coco
butter diet (Harlan Teklad, Madison, Wis, USA) on the day
ofﬁrstinjectionandmaintainedfortwentyweeks.ThisHCD
was used to ensure the development of atherosclerosis. Mice
fed normal chow diet were included as experimental control
group. Animals were weighed weekly, and all experimental
procedures were performed in accordance with protocols
approved by the Institutional Animal Care and Usage
Committee of the Central Arkansas Veterans Health Care
System at Little Rock.
2.3. High-Resolution Ultrasound Imaging. Ultrasound imag-
ing was done using the Vevo 770 High-Resolution Imaging
system (Visualsonics, Toronto, Canada) with a RMV 707B
transducer having a center frequency of 30MHz. Animal
preparation was done as described earlier [15]. Brieﬂy, each
mouse was anesthetized using 1.5% isoﬂurane (Isothesia,
Abbot Laboratories, Chicago, USA) with oxygen and laid
supine on a thermostatically heated platform with all legs
taped to ECG electrodes for cardiac function monitoring.
Abdominal hair was removed with a shaver and a chemical
h a i rr e m o v e r( C h u r c h&D w i g h tC o . ,I n c . ,N J ,U S A ) ,a n d
a prewarmed US gel (Medline Industries, Inc., Mundelein,
USA) was spread over the skin as a coupling medium for
the transducer. Two levels of the vessel were visualized:
thoracic region—below the aortic arches to the diaphragm
and the renal region—the upper abdominal region to the
iliac bifurcation. Image acquisition was started on B-mode,
where a long-axis view was used to visualize the length of the
aorta. Next, the scanhead probe was turned 90◦ for a short-
axis view to visualize the cross-sectional area of the aorta.
Individual frames and cine loops (300 frames) were acquired
at all levels of the aorta both in long-axis and short-axis view
and recorded at distances of 1mm throughout the length
of the aorta. For measurement of ﬂow velocity, orientation
of the abdominal aorta on ultrasound was accomplished by4 International Journal of Vascular Medicine
tilting the platform and the head of mouse down with the
transducer probe towards the feet and tail of the mouse.
This positioning ensured the Doppler angle to be less than
60◦ for accurate measurements of blood ﬂow velocity in the
pulse wave Doppler (PW) mode within abdominal aorta.
Measurementsanddataanalysiswasperformedoﬀlineusing
the customized version of Vevo 770 Analytical Software from
both the longitudinal and transverse images. The complete
imaging for each mouse lasted for about 25–30 minutes.
2.4. Measurement of Plasma Cholesterol. Plasma levels of
totalcholesterolforAAV8/hSTAT3 andAAV8/Neo micewere
measuredbyVetScan VS2 (ABAXIS,Union City, Calif) atthe
Veterans Animal Laboratory (VAMU).
2.5. hSTAT3 and IL-10 Gene Expression Analysis Using Real-
Time Quantitative Reverse Transcription PCR (qRT-PCR).
Total RNA from aorta of three mice was extracted with
TRIzol extraction (Invitrogen Carlsbad, Calif) according
to the manufacturer’s instructions. cDNA was synthesized
using random hexamer primers and RNase H-reverse
transcriptase (Invitrogen, Carlsbad, Calif). QRT-PCR was
performed using the Applied Biosystems Fast 7900HT
real-time PCR system (Applied Biosystems, Foster City,
Calif) as described in [9]. We designed qRT-PCR speciﬁc
primers for analyzing hSTAT3 and IL-10 using Probe-
Finder (http://www.roche-applied-science.com) web-based
software from Human and Mouse Universal ProbeLibrary
from Roche Applied Science. The results were analyzed using
SDS 2.3 relative quantiﬁcation (RQ) manager software. The
comparativethresholdcycles(Ct)valueswerenormalizedfor
GAPDH reference genes and compared with a calibrator by
the 2−ΔΔCt method.
3. Results
3.1. AAV8 Delivers hIL-10 and hSTAT3. Both IL-10 and
STAT3 have been shown to inhibit atherosclerosis in an
animal model [4–6, 9], and both are in the same anti-
inﬂammatorysignaltransductionpathway,withIL-10acting
through STAT3 [7, 8]. Because of this we reasoned that the
delivery of both genes together may result in a synergistic
higher level of anti-inﬂammatory activity, which is depicted
in Figure 1. To test this hypothesis and the eﬃcacy of IL-
10-plus-STAT-3 dual gene delivery we delivered both into
LDLR KO mice using AAV8 and placed them on high
cholesterol diet (HCD). An AAV/Neomycin resistance gene
(Neo) vector was also used as a null, nontherapeutic control.
Vector structures are shown in Figure 2(a) and the overall
experimental scheme in Figure 2(b). Upon time of harvest,
a portion of mice were sacriﬁced to determine the success of
gene delivery by analyzing hSTAT3 mRNA expression in the
aorta using qRT-PCR analysis. This analysis utilized mRNA
isolated from 3 mice aortas from each group, harvested at
week 20. Representative results for hSTAT3 and hIL-10 are
shown in Figure 3(a), and both were observed to be highly
expressed in aortas of appropriately treated animals but not
AAV/Neo-injected or control animals.
A
A
V
/
N
e
o
A
A
V
/
h
S
T
A
T
3
A
A
V
/
h
I
L
-
1
0
A
A
V
/
h
I
L
-
1
0
+
A
A
V
/
h
S
T
A
T
3
c
t
r
l
HCD
550
525
500
475
450
425
400
375
350
325
300
275
S
y
s
t
o
l
i
c
ﬂ
o
w
v
e
l
o
c
i
t
y
(
m
m
/
s
)
P = 0.01
N
o
r
m
a
l
d
i
e
t
Figure 4: Systolic blood velocity. High-resolution ultrasound
(HRUS) was used to measure blood ﬂow velocities in the lumenal
center of the abdominal region of the aorta in 3–5 animals from
each group. Shown is a quantiﬁcation of the results. Note that the
hSTAT3-treated, the hIL-10-treated, and the hSTAT3-plus-hIL-10-
treated animals all had signiﬁcantly lower blood velocity than the
AAV/Neo animals.
3.2. Therapeutic hSTAT3, hIL-10, or hSTAT3-Plus-hIL-10
Gene Delivery Inhibits Aortic Blood Flow Velocity with Equal
Eﬃcacy. Following demonstration of successful transgene
delivery studied the eﬀects of the transgene. Figure 3(b)
shows that hSTAT3-treated animals had total cholesterol
levelscomparabletoNeo-treatedHCD-fedanimals;however
hIL-10-treated animals were statistically lower. Yet it was
found that the dual hIL-10-plus-hSTAT3-treated animals
had cholesterol levels which trended higher than either hIL-
10- or hSTAT3-treated animals. Regarding animal weights,
all treatments were statistically the same as normal diet (ND)
controls but trended higher.
We utilized blood ﬂow velocity measurement as a novel
technique to quantify atherosclerosis in the mice. Systolic
blood ﬂow velocity in the lower abdominal region of the
aorta was quantiﬁed by high-resolution ultrasound (HRUS)
imaging system Vevo 770 with measurements taken on
three to ﬁve animals. Figure 4 shows the quantiﬁed the
systolic blood velocity from ﬁve separate measurements on
each animal. As shown, the AAV/Neo-HCD-treated animals,
with the highest lipid deposition, displayed the highest
ﬂow velocity. Moreover, all three therapeutic treatments had
markedly lower ﬂow velocity, very similar to that in normal-
diet-fed control animals. Thus all three treatments showed
antiatherosclerotic eﬃcacy, yet the dual gene treatment
was not statistically improved over the individual gene
treatments, nor did dual gene delivery trend towards higher
eﬃcacy.
3.3. Therapeutic hSTAT3, hIL-10, and hSTAT3-Plus-hIL-10
Gene Delivery Inhibits Aortic Structural Changes Associated
with Atherosclerosis with Equal Eﬃcacy. Next structuralInternational Journal of Vascular Medicine 5
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Figure 5: Analysis of the aortic lumen by high-resolution ultrasound (HRUS). HRUS was used to measure the cross-sectional area of the
thoracic and renal regions of the aortas in 3–5 animals from each animal group. (a) shows quantiﬁcation of the cross-sectional area for the
thoracic region of the aorta. Note that the hSTAT3-treated, the hIL-10-treated, and the hSTAT3-plus-hIL-10-treated animals all had a much
larger cross sectional area than the AAV/Neo-treated animals, indicating signiﬁcant eﬃcacy. Similarly in (b), quantiﬁcation of the data for
the renal region of the aorta shows a much larger lumen size for the hSTAT3-, hIL-10-, and hSTAT3-plus-hIL-10-treated animals compared
to AAV/Neo-treated animals.
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Figure 6: Analysis of the aortic wall thickness by HRUS. HRUS was used to measure the wall thickness of the aorta. (a) shows quanitiﬁcation
of the thoracic region of the aortas in 3–5 animals from each animal group. Note that the hSTAT3-, hIL-10-, and hSTAT3-plus-hIL-10-
treated animals had thinner wall thicknesses than the Neo-treated animals, indicating signiﬁcant eﬃcacy. (b) shows quantiﬁcation of the
renal region of the aortas in 3–5 animals from each animal group.
changes in the aortas resulting from the various treat-
ments were quantiﬁed using HRUS imaging. Multiple
measurements were made in three to ﬁve animals from each
group and compared. The measurements were made in the
same indicated site (see Section 2). The cross-sectional area
of the lumen of the thoracic region of the aorta was one
measurement taken, with ﬁve readings from each animal.
Figure 5(a) shows the quantiﬁed results for the thoracic
region of the aorta. The AAV/Neo-HCD-treated positive
control animals displayed the smallest cross sectional lumen
area, consistent with signiﬁcant atherosclerosis. In contrast,
allthreetherapeutictreatments(hSTAT3,hIL-10orhSTAT3-
plus-hIL-10) had much larger lumens than Neo-treated-
HCDcontrols,andthisdiﬀerencewasstatisticallysigniﬁcant.6 International Journal of Vascular Medicine
Normaldietcontrolanimalshadthelargestlumen.Therenal
region of the aorta showed a similar pattern to the thoracic
aorta, as shown in Figure 5(b), with AAV/Neo-HCD-treated
having the smallest and all three therapeutic treatments
having statistically signiﬁcant larger lumens. Thus, again, all
three treatments showed antiatherosclerotic eﬃcacy, yet the
dual gene treatment was not statistically improved over the
individual gene treatments.
The wall thickness of the thoracic region of the aorta was
yet another measurement made, with data from three to ﬁve
animals and ﬁve readings from each animal. Figure 6 shows
the quantiﬁed results for the thoracic region of the aorta.
TheAAV/Neo-treatedanimalsdisplayedthethickestthoracic
walls, and all three therapeutic treatments gave statistically
thinner walls, (P = 0.05). Yet, again, dual gene delivery failed
to improve therapeutic eﬃcacy.
4. Discussion
This study is the ﬁrst attempt at using dual gene therapy
within a single signal transduction pathway with a believed
beneﬁcial phenotype with the hypothesis that improved eﬃ-
cacywillresult.BothIL-10andSTAT3areanti-inﬂammatory
genes within the same signal transduction pathway. Because
of this we hypothesized that a synergistic anti-inﬂammatory
eﬀect or enhanced therapeutic eﬀect might be observed by
both AAV8/hIL-10 plus AAV8/hSTAT3 dual gene delivery
in LDLR KO mouse on HCD. This study demonstrates
that there was no enhanced eﬃcacy when both genes
were delivered together over that of the individual genes.
One possible explanation for this lack of eﬀect is that
the two genes were delivered by separate AAV vectors and
thus likely that very few cells were receiving and actively
expressingbothtransgenes.Iftheproteinsofbothgeneswere
intracellular then this explanation would likely be correct
and fully prevent gene cooperation. However, while hSTAT3
is intracellular, IL-10 is a secreted protein and its activity
should be eﬀective over an area through its diﬀusion. Thus,
we think that this explanation is not a viable mechanism
as to why there is no additive or synergistic therapeutic
eﬀect by this approach. Another possible contributor to the
lack of enhancement is that IL-10 trends to have a greater
eﬀect than STAT3; thus what we may be viewing is only the
dominant IL-10 eﬀect. Alternatively, the lack of improved
eﬃcacy by dual IL-10/STAT3 delivery may also suggest
that another IL-10 pathway is more eﬀective in inhibiting
inﬂammation than the STAT3 pathway. Yet enhancement
of the PI3K pathway would seem inappropriate as PI3k
expression appears positively associated with atherosclerosis
[16].
Cholesterol levels seen in the dual-gene-treated ani-
mals were higher than in either individual gene-treated
animals (statistically signiﬁcant for hIL-10 versus hIL-10-
plus-hSTAT3). As both IL-10 and STAT3 are individually
associated with lower cholesterol levels [5, 6, 9], these
data may suggest that some type of negative regulatory
interference between these two gene’s functions and their
downstream signaling is taking place. Additionally, their
individual mechanisms for lowering cholesterol may also
be abrogated. The mechanism of how each lowers blood
c h o l e s t e r o ll e v e l si sp r e s e n t l yu n c l e a r .
Yet another possibility for the failure of IL-10 and STAT3
to cooperate may be the “crossroads” position of STAT3
in the transduction of signaling from multiple receptors,
beyond IL-10/IL-10R interaction. Other important signaling
pathways which require STAT3 signaling include IL-6 [17],
IL-17 [18], Ang II [19], and thrombin [20]. While it is
unclear which of these pathways (or others) is active and
might serve to inhibit the IL-10-STAT3 signaling pathway,
this study reminds us of the complexity of cellular signaling
and the need to determine signaling pathway dominance or
interference when medically signiﬁcant issues of IL-10 and
STAT3 are at issue. An alternative gene pair which might be
tried would be IL-10 plus IL10R1. This would concentrate
augmentation at only the ligand-receptor level, and the
complexities of STAT3 overexpression might be avoided.
It is surprising that IL-10 and STAT3 overexpression
should apparently “knock out” each other’s cholesterol
regulation phenotype as well as limit each other’s antiathero-
genesis phenotype. Due to our negative results we did
not investigate the failure of cooperation between IL-10
and STAT3 any further. Pursuing the mechanism of action
of negative data is unjustiﬁed. However, these results of
noncooperation indicate that our understanding of the IL-
10 and STAT3 pathways is incomplete and that gene pairs
utilized in dual gene therapies may give surprising results
diﬀerent than what initial logical planning might suggest.
However, we believe the dual gene delivery approach will
ultimately result in enhanced eﬃcacy if the gene partners
chosen are mechanistically appropriate and compatible. In
spite of the negative results presented here, the investigation
and discovery therapeutic gene synergisms, but not between
IL-10 and STAT3, has merit and needs to be pursued.
Acknowledgments
This study was funded by VA Merit Review and AHA Grants
to Paul L. Hermonat.
References
[1] R. Ross, “Atherosclerosis—an inﬂammatory disease,” The New
EnglandJournalofMedicine,vol.340,no.2,pp.115–126,1999.
[2] P. O. Bonetti, L. O. Lerman, and A. Lerman, “Endothelial
dysfunction. A marker of atherosclerotic risk,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 168–175,
2003.
[3] S. Sela, R. Shurtz-Swirski, J. Awad et al., “The involvement
of peripheral polymorphonuclear leukocytes in the oxidative
stressandinﬂammationamongcigarettesmokers,”IsraelMed-
ical Association Journal, vol. 4, no. 11, pp. 1015–1019, 2002.
[4] Y. Liu, D. Li, J. Chen et al., “Inhibition of atherogenesis in
LDLRknockoutmicebysystemicdeliveryofadeno-associated
virus type 2-hIL-10,” Atherosclerosis, vol. 188, no. 1, pp. 19–27,
2006.
[5] S. Chen, M. H. Kapturczak, C. Wasserfall et al., “Interleukin
10 attenuates neointimal proliferation and inﬂammation in
aortic allografts by a heme oxygenase-dependent pathway,”International Journal of Vascular Medicine 7
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 20, pp. 7251–7256, 2005.
[6] T. Yoshioka, T. Okada, Y. Maeda et al., “Adeno-associated
virus vector-mediated interleukin-10 gene transfer inhibits
atherosclerosis in apolipoprotein E-deﬁcient mice,” Gene
Therapy, vol. 11, no. 24, pp. 1772–1779, 2004.
[7] L. M. Williams, U. Sarma, K. Willets, T. Smallie, F. Brennan,
a n dB .M .J .F o x w e l l ,“ E x p r e s s i o no fc o n s t i t u t i v e l ya c t i v e
STAT3 can replicate the cytokine-suppressive activity of
interleukin-10 in human primary macrophages,” Journal of
Biological Chemistry, vol. 282, no. 10, pp. 6965–6975, 2007.
[ 8 ]K .C .E lK a s m i ,J .H o l s t ,M .C o ﬀre et al., “General nature of
the STAT3-activated anti-inﬂammatory response,” Journal of
Immunology, vol. 177, no. 11, pp. 7880–7888, 2006.
[ 9 ]J .A .K h a n ,M .C a o ,B .Y .K a n g ,Y .L i u ,J .L .M e h t a ,a n d
P. L. Hermonat, “AAV/hSTAT3-gene delivery lowers aortic
inﬂammatory cell inﬁltration in LDLR KO mice on high
cholesterol,” Atherosclerosis, vol. 213, no. 1, pp. 59–66, 2010.
[10] B. Vogelstein and K. W. Kinzler, “Cancer genes and the
pathways they control,” Nature Medicine,v o l .1 0 ,n o .8 ,p p .
789–799, 2004.
[11] P. L. Hermonat and N. Muzyczka, “Use of adeno-associated
virus as a mammalian DNA cloning vector: transduction of
neomycin resistance into mammalian tissue culture cells,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 81, no. 20 I, pp. 6466–6470, 1984.
[12] J. D. Tratschin, M. H. P. West, T. Sandbank, and B. J. Carter,
“A human parvovirus, adeno-associated virus, as a eucaryotic
vector: transient expression and encapsidation of the procary-
otic gene for chloramphenicol acetyltransferase,” Molecular
and Cellular Biology, vol. 4, no. 10, pp. 2072–2081, 1984.
[13] P. L. Hermonat, M. A. Labow, R. Wright, K. I. Berns, and N.
Muzyczka, “Genetics of adeno-associated virus: isolation and
preliminary characterization of adeno-associated virus type 2
mutants,”JournalofVirology,vol.51,no.2,pp.329–339,1984.
[14] A. K. Zaiss, Q. Liu, G. P. Bowen, N. C. W. Wong, J. S. Bartlett,
and D. A. Muruve, “Diﬀerential activation of innate immune
responses by adenovirus and adeno-associated virus vectors,”
Journal of Virology, vol. 76, no. 9, pp. 4580–4590, 2002.
[15] B. Martin-McNulty, J. Vincelette, R. Vergona, M. E. Sullivan,
and Y. X. Wang, “Noninvasive measurement of abdominal
aortic aneurysms in intact mice by a high-frequency
ultrasound imaging system,” Ultrasound in Medicine and
Biology, vol. 31, no. 6, pp. 745–749, 2005.
[16] A. Fougerat, S. Gayral, N. Malet, F. Briand-Mesange, M.
Breton-Douillon, and M. Laﬀargue, “Phosphoinositide
3-kinases and their role in inﬂammation: potential clinical
targetsinatherosclerosis?” ClinicalScience,vol.116,no.11-12,
pp. 791–804, 2009.
[17] X. Zhang, P. Yin, D. Di et al., “IL-6 regulates MMP-10
expression via JAK2/STAT3 signaling pathway in a human
lung adenocarcinoma cell line,” Anticancer Research, vol. 29,
no. 11, pp. 4497–4501, 2009.
[18] S. Zhang, M. Zheng, R. Kibe et al., “Trp53 negatively regulates
autoimmunity via the STAT3-Th17 axis,” The FASEB Journal,
vol. 25, no. 7, pp. 2387–2398, 2011.
[19] F. Amiri, S. Shaw, X. Wang et al., “Angiotensin II activation of
theJAK/STATpathwayinmesangialcellsisalteredbyhighglu-
cose,”KidneyInternational,vol.61,no.5,pp.1605–1616,2002.
[ 2 0 ]X .C h e n ,W .L i u ,J .W a n g ,X .W a n g ,a n dZ .Y u ,“ S T A T 1a n d
STAT3 mediate thrombin-induced expression of TIMP-1 in
human glomerular mesangial cells,” Kidney International, vol.
61, no. 4, pp. 1377–1382, 2002.